Argenx Eyes Larger Patient Pool Following Expanded FDA Nod For Lead Drug For Neuromuscular Disease

Argenx shares rose after the FDA approved VYVGART for use in adult patients with generalized myasthenia gravis, expanding the drug’s approved market. The decision is a clear regulatory and commercial positive for the company and should support revenue expectations. The news is company-specific and likely to influence ARGX shares more than the broader market.

Analysis

Argenx shares rose after the FDA approved VYVGART for use in adult patients with generalized myasthenia gravis, expanding the drug’s approved market. The decision is a clear regulatory and commercial positive for the company and should support revenue expectations. The news is company-specific and likely to influence ARGX shares more than the broader market.